Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TRAX
FIRST TRACKS BIOTHERAPEUTICS INC
NASDAQ
$40.75
▼ DOWN 4.14% (-1.76)

KEY STATISTICS

Market Cap$1.48 B
52w High$49.91
52w Low$14.72
Dividend Yield—
Frequency—
P/E-8.65
Volume275.32K
Shares Out.34.89M

COMPANY

LEADERSHIP

Daniel R. Faga
CHIEF EXECUTIVE
Daniel R. Faga

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 20, 2026
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
104

PRICE TARGET

Target High$95.00
Target Low$46.00
Target Median$60.00
Target Consensus$63.29

PRICE

$40.75 ▼ DOWN 4.14% (−$1.76)
$40.80$41.20$41.609:30 AM10:15 AM11:01 AM11:46 AM12:31 PM1:17 PM2:02 PM40.75

About First Tracks Biotherapeutics Inc

https://www.firsttracksbio.com ↗

First Tracks Biotherapeutics, Inc. develops immunology therapeutics for autoimmune and inflammatory diseases, focusing on clinical-stage programs like rosnilimab, ANB033, and ANB101, and is based in San Diego, CA.

INDUSTRY

Biotechnology

A PRODUCT FIRST TRACKS BIOTHERAPEUTICS INC IS KNOWN FOR

ANB033
ANB033

ANB033, a clinical-stage CD122 antagonist by First Tracks Biotherapeutics, is in Phase 1b trials for celiac disease and eosinophilic esophagitis, focusing on autoimmune and inflammatory disease therapies.

COMPETITORS

COMPETITOR
KYTX COMPARE
NVS COMPARE
RIGL COMPARE
SNY COMPARE
TEVA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
119
LISTED HERE
21
RANKED BY POSITION SIZE
VTI
0.00% · 1.1M
XBI
0.39% · 992.2K
IWM
0.03% · 598.5K
SCHA
0.03% · 126.8K
OMFS
0.58% · 35.8K
LABU
0.26% · 33.1K
XRSU.L
0.03% · 21.2K
CANC
0.38% · 19.3K
DFAS
0.01% · 18.8K
BBC
1.58% · 17.8K
AVUS
0.00% · 15.8K
FESM
0.01% · 15.0K
RSSL
0.03% · 11.1K
HELX
0.72% · 5.0K
SGRW
0.52% · 3.2K
RTWO.L
0.05% · 2.8K
BIB
0.05% · 1.2K
RFLR
0.06% · 1.2K
PWS
0.08% · 432
RESM
0.05% · 66
ESSC
0.00% · 14

INSTITUTIONAL OWNERSHIP

SHARES OWNED
51.15%
HOLDERS
125
TOP 12 OF 125 · RANKED BY POSITION SIZE
Ecor1 Capital, LLC
3.2M sh · $63.87M
Tcg Crossover Management, LLC
2.9M sh · $58.25M
Fmr LLC
2.1M sh · $41.33M
Affinity Asset Advisors, LLC
2.0M sh · $40.88M
Blackrock, Inc.
2.0M sh · $39.51M
Vestal Point Capital, LP
1.0M sh · $20.38M
Woodline Partners LP
917.2K sh · $18.45M
Sanofi
821.9K sh · $16.54M
Morgan Stanley
781.5K sh · $15.72M
683 Capital Management, LLC
750.0K sh · $15.09M
Adage Capital Partners Gp, L.L.C.
729.0K sh · $14.67M
Balyasny Asset Management L.P.
714.9K sh · $14.38M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
ANAPTYSBIO, INC
Sale · 100 shares
2026-04-20
★
10 PERCENT OWNER
ANAPTYSBIO, INC
— · —
2026-04-01